HUP0202049A2 - Egyebek mellett osteoporosis kezelésére alkalmazható indolszármazékok - Google Patents

Egyebek mellett osteoporosis kezelésére alkalmazható indolszármazékok

Info

Publication number
HUP0202049A2
HUP0202049A2 HU0202049A HUP0202049A HUP0202049A2 HU P0202049 A2 HUP0202049 A2 HU P0202049A2 HU 0202049 A HU0202049 A HU 0202049A HU P0202049 A HUP0202049 A HU P0202049A HU P0202049 A2 HUP0202049 A2 HU P0202049A2
Authority
HU
Hungary
Prior art keywords
alkyl
compounds
osteoporosis
treatment
group
Prior art date
Application number
HU0202049A
Other languages
English (en)
Inventor
Carlo Farina
Stefania Gagliardi
Pietro A.T. Novella
Original Assignee
Glaxosmithkline S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline S.P.A. filed Critical Glaxosmithkline S.P.A.
Publication of HUP0202049A2 publication Critical patent/HUP0202049A2/hu
Publication of HUP0202049A3 publication Critical patent/HUP0202049A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)

Abstract

A találmány (I) általános képletű vegyületekre - amelyek képletében R1és R2 jelentése alkoxicsoport vagy halogénatom: R3 és R4 jelentésehidrogénatom, alkoxi-, aril-(alkoxi)-, hidroxi-, karboxi-(alkoxi)-,hidroxi-(alkoxi)-, dihidroxi-(alkoxi)-,[mono- és di(alkil)-amino]-(alkoxi)- vagy amino-(alkoxi)-csoport; és R5 jelentése -NRsRtáltalános képletű csoport, amelyben Rs és Rt jelentése hidrogénatom,adott esetben szubsztituált alkil- vagy heterociklusos csoport -sóikra vagy szolvátjaikra, a vegyületek előállítási eljárására, avegyületeket tartalmazó, többek között osteoporosis kezelésérealkalmas gyógyszerkészítményekre, valamint a vegyületek és agyógyszerkészítmények gyógyászati felhasználására vonatkozik. Ó
HU0202049A 1999-06-18 2000-06-16 Indole derivatives and their use for the treatment of osteoporosis amongst other applications HUP0202049A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914371.1A GB9914371D0 (en) 1999-06-18 1999-06-18 Novel compounds

Publications (2)

Publication Number Publication Date
HUP0202049A2 true HUP0202049A2 (hu) 2002-11-28
HUP0202049A3 HUP0202049A3 (en) 2003-12-29

Family

ID=10855696

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202049A HUP0202049A3 (en) 1999-06-18 2000-06-16 Indole derivatives and their use for the treatment of osteoporosis amongst other applications

Country Status (30)

Country Link
US (2) US6787550B1 (hu)
EP (1) EP1212317B1 (hu)
JP (1) JP2003503490A (hu)
KR (1) KR100701109B1 (hu)
CN (1) CN1179960C (hu)
AR (1) AR024390A1 (hu)
AT (1) ATE276245T1 (hu)
AU (1) AU768726B2 (hu)
BR (1) BR0011708A (hu)
CA (1) CA2376657A1 (hu)
CO (1) CO5200757A1 (hu)
CZ (1) CZ301697B6 (hu)
DE (1) DE60013859T2 (hu)
DK (1) DK1212317T3 (hu)
ES (1) ES2226870T3 (hu)
GB (1) GB9914371D0 (hu)
GC (1) GC0000341A (hu)
HK (2) HK1048468B (hu)
HU (1) HUP0202049A3 (hu)
IL (2) IL147012A0 (hu)
MX (1) MXPA01013277A (hu)
MY (1) MY129425A (hu)
NO (1) NO322313B1 (hu)
NZ (1) NZ516131A (hu)
PL (1) PL352964A1 (hu)
PT (1) PT1212317E (hu)
TR (1) TR200103683T2 (hu)
TW (1) TWI248440B (hu)
WO (1) WO2001002388A1 (hu)
ZA (1) ZA200200177B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615575B2 (en) 2003-02-13 2009-11-10 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2007523873A (ja) * 2003-07-15 2007-08-23 スミスクライン・ビーチャム・コーポレイション 新規化合物
ITMI20040875A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici utili per il trattamento della resistenza agli agenti antitumorali
JP5031569B2 (ja) 2004-09-17 2012-09-19 イデニク ファルマセウチカルス インコーポレーテッド Ｈｉｖ阻害剤としてのホスホインドール
WO2006041874A2 (en) * 2004-10-04 2006-04-20 Myriad Genetics, Inc. Compounds for alzheimer's disease
US7833805B2 (en) * 2004-10-21 2010-11-16 University Of Cincinnati Selectively permeable membranes on porous substrates
JP5070050B2 (ja) * 2005-07-20 2012-11-07 正徳 染井 トリプトファン誘導体及びその用途
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
MX2008002166A (es) * 2005-08-15 2008-04-22 Irm Llc Compuestos y composiciones como mimeticos de trombopoietina (tpo).
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
EP1779848A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
CA2637373A1 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1976377A4 (en) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
WO2007092729A2 (en) 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2008008895A1 (en) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for the treatment of diabetes and related disorders
MX2009003410A (es) 2006-09-29 2009-07-17 Idenix Pharmaceuticals Inc Fosfoindoles enantiomericamente puros como inhibidores de vih.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EP2396082B1 (en) 2009-02-16 2013-07-31 Nogra Pharma Limited Methods for treating hair related conditions
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
BR112013005552A2 (pt) * 2010-09-08 2016-05-03 Bristol Myers Squibb Co análogos de piperazina como antivirais de influenza de amplo espectro
WO2012045451A1 (en) 2010-10-05 2012-04-12 Ludwig-Maximilians-Universitaet Muenchen Novel therapeutic treatment of progranulin-dependent diseases
WO2012078416A2 (en) * 2010-12-06 2012-06-14 Rfs Pharma, Llc Monophosphate prodrugs of dapd and analogs thereof
EP2811993B1 (en) 2012-02-09 2019-10-09 Nogra Pharma Limited Methods of treating fibrosis
NZ631049A (en) 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
US11905232B2 (en) 2019-02-08 2024-02-20 Nogra Pharma Limited Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
CN113024432A (zh) * 2019-12-24 2021-06-25 上海科胜药物研发有限公司 一种氨磺必利药典杂质的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
SK93297A3 (en) * 1995-01-10 1998-02-04 Smithkline Beecham Spa Indole derivatives, method for their producing, pharmaceutical comosition containing the same, and their use
PL330994A1 (en) * 1996-07-09 1999-06-21 Smithkline Beecham Spa Indolic derivatives for use in treating osteoporosis
NZ505060A (en) * 1997-12-24 2002-09-27 Smithkline Beecham Lab 2-Aryl or heterocyclyl substituted indole derivatives useful for the treatment of osteoporosis

Also Published As

Publication number Publication date
WO2001002388A1 (en) 2001-01-11
PT1212317E (pt) 2005-02-28
DE60013859D1 (de) 2004-10-21
DK1212317T3 (da) 2005-01-24
CZ301697B6 (cs) 2010-05-26
BR0011708A (pt) 2002-05-21
EP1212317B1 (en) 2004-09-15
CO5200757A1 (es) 2002-09-27
CZ20014496A3 (cs) 2002-07-17
MY129425A (en) 2007-03-30
HK1048468A1 (en) 2003-04-04
JP2003503490A (ja) 2003-01-28
DE60013859T2 (de) 2005-09-29
HK1049164A1 (zh) 2003-05-02
AR024390A1 (es) 2002-10-02
NO20016149L (no) 2001-12-17
HK1048468B (zh) 2005-07-29
PL352964A1 (en) 2003-09-22
KR20020025079A (ko) 2002-04-03
ZA200200177B (en) 2003-09-23
KR100701109B1 (ko) 2007-03-29
IL147012A (en) 2007-06-03
NO20016149D0 (no) 2001-12-17
AU5816500A (en) 2001-01-22
CN1370159A (zh) 2002-09-18
NO322313B1 (no) 2006-09-11
US20040235930A1 (en) 2004-11-25
NZ516131A (en) 2003-10-31
MXPA01013277A (es) 2002-06-04
TR200103683T2 (tr) 2003-01-21
AU768726B2 (en) 2004-01-08
HUP0202049A3 (en) 2003-12-29
IL147012A0 (en) 2002-08-14
EP1212317A1 (en) 2002-06-12
GB9914371D0 (en) 1999-08-18
GC0000341A (en) 2007-03-31
ATE276245T1 (de) 2004-10-15
ES2226870T3 (es) 2005-04-01
CA2376657A1 (en) 2001-01-11
CN1179960C (zh) 2004-12-15
TWI248440B (en) 2006-02-01
US6787550B1 (en) 2004-09-07

Similar Documents

Publication Publication Date Title
HUP0202049A2 (hu) Egyebek mellett osteoporosis kezelésére alkalmazható indolszármazékok
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
HUP0401339A2 (hu) Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0003381A2 (hu) Topiramát és származékai alkalmazása mániás depressziós bipoláris rendellenesség kezelésére alkalmas gyógyszerek előállítására
HUP0303084A2 (hu) Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
MY102866A (en) Amide derivatives.
IL138516A0 (en) Benzenesulfonamide derivatives and their use as medicaments
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0203228A2 (hu) Szubsztituált indolszármazékok az NFKB-aktivitás módosítására, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0402225A2 (hu) Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0204246A2 (hu) Új tiazolo[4,5-d]pirimidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0303891A2 (hu) Gyógyhatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0401638A2 (hu) Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények
HUP0102058A2 (hu) Új 2-alkil-szubsztituált imidazolvegyületek, eljárás előállításukra, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
DK0490772T3 (da) 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem
HUP0400250A2 (hu) 5-HT6 és/vagy 5-HT7 szerotonin receptorok ligandumaként alkalmazott 5-halogén-triptamin-származékok, előállításuk és alkalmazásuk gyógyszerkészítmények előállítására
HUP0102813A2 (hu) Perindopril-terc-butil-amin-só új béta-kristályos formája, eljárás ennek előállítására és ezt tartalmazó gyógyászati készítmények
AR024145A1 (es) Derivados de 5-fenil-pirimidina
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
HUP0401235A2 (hu) 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0104033A2 (hu) Benzoilpiridazin-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk
HUP0104963A2 (hu) Bőrbetegségek kezelésére szolgáló készítmények
HUP0402602A2 (hu) Eljárás echinokandin-származékok előállítására, ezek alkalmazása, ezeket tartalmazó gyógyszerkészítmények és intermedierek
HUP0300295A2 (hu) Helyettesített benzamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: 3-V BIOSCIENCES INC., US

Free format text: FORMER OWNER(S): GLAXOSMITHKLINE S.P.A., IT; NIKEM RESEARCH S.R.L., IT

FD9A Lapse of provisional protection due to non-payment of fees